Sendatu Therapeutics is a biotechnology company focused on the engineering of novel AAV vectors for gene therapy delivery.
AAVitruvian is a tissue-specific capsid selection platform that leverages the power of artificial intelligence (AI) to design AAV capsids that can deliver precise payloads to target tissues with improved function.
-NrWOd.webp)
The efficacy of the AAVitruvian platform has been validated in-vitro and in-vivo.
A team with expertise in AAV vectorology, bioinformatics and AI.
Our machine learning models trained in custom datasets can screen billions of variants to identify optimal sequences for specific therapeutic targets.
Rapid identification of lead candidates for validation and advancement to preclinical testing.
Cambridge, Massachusetts,
United States
and
Sydney, New South Wales,
Australia
contact@sendatutx.com